Form 4: Charles River Laboratories Director Llado Acquires Shares and Options

Director George Llado Sr. reports acquisition of common stock and stock options in Charles River Laboratories.

Summary

• On May 13, 2024, George Llado Sr., a director of Charles River Laboratories International, Inc., acquired 559 shares of common stock at $228.41 per share.
• Llado also acquired 306 shares of common stock as a grant in lieu of director service fees.
• Additionally, Llado acquired 1,311 stock options with an exercise price of $228.41, exercisable starting May 13, 2025, or the day before the next annual meeting, and expiring on May 13, 2034.
• Following these transactions, Llado directly owns 3,349 shares of common stock and 1,311 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The director's purchase could be seen as a positive signal, but it's not a major event.

Positives

• Director's acquisition of shares and options signals confidence in the company's future.
• Grant of shares in lieu of fees demonstrates cost management.

Future Outlook

The unvested restricted stock units and stock options vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, in their company's stock.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates